Nephrology · Acute Kidney InjuryTrial Updateclinicalmid-term

SP16 Trial Aims to Prevent Acute Kidney Injury in CKD Patients Undergoing Cardiac Surgery

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/23/2026, 12:33:23 PM

Assessment confidence: 55% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of SP16 is significant as it targets a critical unmet need in preventing acute kidney injury during cardiac surgery for patients with chronic kidney disease. Successful outcomes could enhance Serpin Pharma's positioning in nephrology and lead to new therapeutic avenues. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

Strategic Assessment

Positive trial results could enhance Serpin Pharma's portfolio and open avenues for further development in related indications, impacting strategic partnerships and investment. The strongest clinical anchor is Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Nephrology · Acute Kidney Injury, 5 regulatory and 4 competitive items passed relevance filtering for Serpin Pharma, LLC.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from [Ad hoc announcement pursuant to Art.. If successful, SP16 could position Serpin Pharma as a key player in the nephrology space, particularly in surgical settings where kidney injury risk is high.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Regulatory pathway relevance (indication). Relevant agencies in corpus: FDA, MHRA. The trial's results will influence the regulatory pathway for SP16, impacting its approval timeline and market entry, which is crucial for Serpin Pharma's growth strategy.

Key Risks

Elevated medium regulatory exposure for Serpin Pharma, LLC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If SP16 demonstrates efficacy, it could capture market share in a niche but vital area of nephrology, potentially leading to increased revenues and strategic partnerships.
The FDA has approved changes to the Drugs Facts Label of the over-the-counter (OTC) weight loss drug, alli (orlistat) 60 mg capsules, to warn of risks of acute kidney injury, which is a rare side effect of the medication.
How we engage and involve patients and the public in our regulatory decision-making.
Upside for Serpin Pharma, LLC may improve if 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia (ClinicalTrials.gov) delivers favorable follow-through.
Positive trial results could enhance Serpin Pharma's portfolio and open avenues for further development in related indications, impacting strategic partnerships and investment.

What Would Change This Assessment

This becomes more urgent if Monitor trial enrollment progress, interim results, and any announcements regarding efficacy outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (indication)
FDA document
View source
FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During Orthopedic Surgeries in Egyptian Patients.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Left Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Ravulizumab Shows Promise in Reducing Delayed Graft Function in Kidney Transplant Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A qualitative study exploring discharge readiness experiences among patients with esophageal cancer undergoing esophagectomy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leuke
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Serpin Pharma, LLC
patients with chronic kidney disease

Commercial impact

medium

If SP16 demonstrates efficacy, it could capture market share in a niche but vital area of nephrology, potentially leading to increased revenues and strategic partnerships.

Regulatory impact

medium

The trial's results will influence the regulatory pathway for SP16, impacting its approval timeline and market entry, which is crucial for Serpin Pharma's growth strategy.

What to watch

Monitor trial enrollment progress, interim results, and any announcements regarding efficacy outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.